Compliance and Effective Management of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant Chemotherapy by Son, Hyun-Sook et al.
Yonsei Med J   http://www.eymj.org    Volume 50   Number 6   December 2009 796
Oral chemotherapeutic agents play an important role in the management of many
different types of cancer; and it is likely that the use of these drugs will continue to
grow. The use of 5-fluorouracil (5-FU) has been an integral part of many
cytotoxic regimens for the treatment of malignant disease over the past four
decades.
1 Oral fluropyrimidine is also called capecitabine; and it has been shown
to be effective against colon cancer with a disease-free survival that is at least
equivalent to that of fluorouracil-plus-leucovorin treatment.
2
Physicians and oncology nurses must continuously update their knowledge on
current treatments and treatment-related side effects; and they must search for
effective methods to prevent and/or manage the side effects that develop. In
addition, they are responsible for educating their patients about the available
regimens and providing them with accurate information regarding: 1) the drug
names, dosages and when, where, and how treatment will be administered, 2) the
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Purpose: Physicians and oncology nurses must continue to update their knowledge on treatment and treatment-
related side effects, while searching for effective methods to prevent or manage side effects. The objective of our
study was to describe the incidence and response to treatment of the hand-foot syndrome (HFS) and the compliance
with treatment of patients with stage IIB, IIIA, IIIB, and IIIC colon cancer that were treated with capecitabine alone
as adjuvant therapy. Materials and Methods: Between September 2005 and September 2006, 84 patients fulfilled
the inclusion criteria and were included in this retrospective analysis of prospectively collected data. Results: The
treatment compliance rate was 90.5% (76 out of the 84 patients). The HFS developed in 65 patients (77.4%).
Thirty-three patients (50.7%) had grade 1 HFS, 22 patients (33.8%) had grade 2 HFS and 10 patients (15.5%) had
grade 3 HFS, as their most severe episode. For Grade 1 patients, the dose was maintained, and skin barrier cream
and moist exposed burn ointment (MEBO) were applied. For Grade 2 patients, either the dose was maintained or
25% of the dose was reduced; MEBO and supportive care were provided. For Grade 3 patients, one cycle of
chemotherapy was interrupted followed by dose adjustment; MEBO and supportive care were provided.
Conclusion: HFS is manageable if both patients and oncology care teams are educated about HFS associated with
capecitabine. The HFS is treated by patient education, preventive management, ointment application, conservative
management, dose reduction, and interruption of chemotherapy administration.  
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INTRODUCTIONanticipated side effects and 3) the methods used to prevent
side effects as well as the methods used to treat the com-
plications when they do occur.
Although capecitabine is generally well tolerated, many
patients experience side effects that can be controlled by
additional treatments provided by physicians and/or nurses.
The hand-foot syndrome (HFS) is the only clinical adverse
event that commonly occurs with capecitabine treatment.
HFS is also referred to as palmar-plantar erythrodyses-
thesia; and it warrants special attention because it is the
most common dose-limiting toxicity, and the only clinically
significant adverse event that frequently occurs with the
administration of capecitabine when compared to 5-FU/
leucovorin intravenous administration.
2
HFS is a distinctive and relatively common toxic reaction
related to some chemotherapeutic agents.
3 HFS was ini-
tially described by Zuehlke in 1974 in association with
mitone therapy for a hypernephroma.
4 In 1980, it was
referred to as chemotherapy-induced acral erythema and
appeared to be associated with cutaneous exposure to a
variety of chemotherapy drugs.
4 Most patients present with
a prodrome of dysesthesia, usually a tingling sensation of
the palms and soles. In a few days, the condition progresses
to a burning pain sensation in conjunction with a well-
defined swelling and erythema.
3 If the offending drug is
not adjusted, there may be skin breakdown, and desqua-
mation, bullous formation or secondary infections can
occur in severe cases. Therefore, HFS can be a major cause
of reduced compliance and quality of life.
The objective of this study was to determine the incidence
and response to treatment of HFS, and the compliance
with treatment, in patients with stage IIB, IIIA, IIIB, and
IIIC colon cancer that were treated with capecitabine alone
as adjuvant therapy.
Patients
Between September 2005 and September 2006, a total of
420 patients underwent colectomy for colon cancer at
Samsung Medical Center. The inclusion criteria for the
study were 1) pathologic stage IIA, IIIA, IIIB and IIIC
disease according to the TNM classification as proposed
by the American Joint Committee of Cancer 6th edition,
5
2) patients who underwent capecitabine monotherapy
with completion of at least one cycle, 3) an age ≥ 18 years
and 4) an Eastern Cooperative Oncology Group (ECOG)
performance status of two or less. Eighty-four patients ful-
filled the inclusion criteria and they were included in this
retrospective analysis of the prospectively collected data. 
Treatment
Capecitabine was initially administered at 2500 mg/m
2/day
in two daily doses for two weeks, followed by one week of
rest. These cycles were repeated every 21 days for eight
cycles (24 weeks) until disease recurrence, occurrence of
severe toxicity, severe intercurrent illness, or voluntary
withdrawal. The patients were clinically evaluated for
adverse events (especially HFS), and laboratory data were
recorded after the first cycle and at the completion of two
cycles thereafter. 
Evaluation of response and surveillance
Surveillance for response was assessed every three weeks
until the end of the eighth cycle. The patients were examined
before each cycle of treatment. Physical examination, the
serum CEA level (carcino-embryonic antigen) as well as
the serum chemistries and blood counts were obtained
before each cycle of therapy for the first two cycles and
every two cycles thereafter. Chest X-ray and spiral abdo-
minal computed tomography (CT) scanning were performed
every six months for the first three years and annually
thereafter. Colonoscopy was performed every year for the
first five years.
Data collection
An oncology nurse enrolled subjects during the first round
of treatment and collected data on the management of
HFS; the data included five interviews and four phone-call
audits. Oncology nurses monitored the initial treatment
cycle, 1) to educate the patients, pre-medication, 2) to
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MATERIALS AND METHODS
Table 1.Hand-Foot Syndrome Grading Scale (Palmar-Plantar Erythrodysesthesia)*
Grade Functional status Clinical status
1
Discomfort that does not disrupt   Numbness, dysesthesia / paresthesia, tingling, 
normal activities painless swelling or erythema in the hands and feet
2
Discomfort that affects activities  
Painful erythema with swelling of palms and soles
of daily living
3
Severe discomfort, unable to work or   Moist desquamation, ulceration, blistering, severe
perform activities of daily living pain
*This scale applies only for grading hand-foot syndrome and not for describing any other skin event and/or other cutaneous area. Modified 
from Blum, et al.
6carry out the initial assessment, 3) to explain HFS, 4) and
to provide the patients with an information booklet with
appropriate phone numbers for contact. From the second to
the eighth cycle, 1) the nurse checked for the occurrence of
HFS (e.g., time and grade) by interviewing the patients in
the outpatient department, 2) managed the HFS, 3) collected
data from the interviews in the medical record, 4) and
followed up on each cycle by telephone. 
Management of the HFS
The HFS was recorded according to the HFS grading scale
(Table 1).
6 For Grade 1 patient, dose was maintained and
skin barrier cream and moist exposed burn ointment
(MEBO) were applied. For Grade 2 patient, either dose
was maintained or 25% of dose was reduced. MEBO and
Supportive care were applied. For Grade 3 patient, one cycle
was interrupted followed by dose adjustment. MEBO and
supportive care were applied. Application of the Skin barrier
cream was ceased when Grade 2 due to friction accom-
panied with the cream (Fig. 1).
Patient characteristics
A total of 84 patients, including 51 men and 33 women, were
included in the analysis. The median age was 62 (range: 29-
78 years). The patient characteristics are presented in Table 2.
All patients received capecitabine for at least one cycle. The
median number of cycles received was eight cycles. 
Compliance
The treatment compliance rate was 90.5% (76 out of the
84 patients). Eight patients (9.5%) among the 84 discon-
tinued treatment. The reasons for the discontinuation of
treatment were “nausea” in 25% (2/8), “patient request” in
25.5% (2/8), “metastasis to another organ” in 25.0% (2/8),
“hand-foot syndrome” in 12.5% (1/8), and “neutropenia”
in 12.5% (1/8). 
Toxicity
Mild to severe adverse events were reported for 84.5% (71
of the 84 patients). The hand-foot syndrome was the most
common adverse side effect. The incidence of toxicity is
listed in Table 3. The most frequently observed hemato-
logical adverse event was leucocytopenia; however, no
patient had an episode of neutropenic fever. No patient
received prophylactic or therapeutic granulocyte colony
stimulating factor during this study. Gastrointestinal
adverse events were observed more frequently. Eight
patients reported diarrhea (9.5%); and nausea and vomiting
were observed in 29 patients (34.5%). With respect to the
laboratory values, increased transaminase activity was
noted in 10 patients (11.9%) and one patient (1.2%) devel-
oped hyperbilirubinemia. The hand-foot syndrome develop-
ed in 65 patients (77.4%). The clinical manifestations of
the HFS are presented in Fig. 2. There were 90.5% of the
patients that completed the full eight cycles.
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RESULTS
Grade I  
Maintain dose
Apply skin barrier cream & Apply MEBO
(moist exposed burn ointment)
Fig. 1.Management system of hand-foot syndrome.
Table 2.Patient Characteristics
Characteristics Number (n = 84) %
Gender
Male 51 60.7
Female 33 39.3
Age (yrs)
Median 62
Range 29 - 78
Body surface area (m
2)
Median 1.7
Range 1.34 - 2.05
Disease stage at diagnosis 
II 71 84.5
III 13 15.5
Cycle received
Median 8
Range 1 - 8 
Grade II  
Maintain dose or reduce 25% dose
Apply MEBO (moist exposed burn ointment)
Supportive care
Grade III  
Interrupt one cycle
Adjust dose
Apply MEBO (moist exposed burn ointment)
Supportive care
Supportive care
Avoid extremes in temperature, pressure, 
and friction of hand and foot
Cooling the hand and foot
Cushioning sore skin 
Keeping the skin exposed to air 
To prevent excess sweatingSeverity and time course of HFS
For analysis of the severity of the HFS, only the most
severe episode of HFS was considered for each patient.
The grade distribution of the worst episodes among 65
patients with HFS is presented in Table 4. Thirty-three
patients (50.7%) had grade 1 HFS, 22 patients (33.8%) had
grade 2 HFS and 10 patients (15.5%) had grade 3 HFS as
their most severe episode.
The HFS was evaluated at the time of the development
of the first episode and at the time of the worst episode.
Among the 65 patients who had the HFS, 45 patients
(73.9%) had their first episode after the second or more
cycles. The most severe episode occurred during or after
the fourth cycle in 39 patients (60.0%). The first or worst
episode of HFS occurred less frequently within the first
two weeks of initiating chemotherapy. The HFS grade was
higher in the feet than the hands.
HFS response to treatment
At the time of the first treatment medication, the patients
were educated using a booklet for the oral medication used
for HFS management by an oncology nurse. The HFS was
managed by monitoring the side effects and the medica-
tion. In addition, the patients were warned to take special
care of their affected areas. They applied skin emollient
and skin barrier cream. For the cases with Grade 1 HFS,
the treatment continued using the original dose with the
application of a skin barrier cream and MEBO. For Grade
2 HFS, the original dose was maintained with application
of MEBO and supportive care in 13 patients; for nine
patients, 75% of the dosage was maintained with applica-
tion of MEBO and supportive care, according to the condi-
tion of the patient. For grade 3 HFS, the chemotherapy was
Capecitabine for Colon Cancer Patients
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Fig. 2. Clinical manifestations of hand-foot syndrome (HFS). (A) Grade 1 HFS. (B)
Characteristic erythema associated with moderate HFS, grade 2. (C) Grade 3
HFS associated with progressed moist desquamation with the patient in an
extremely painful and debilitated condition.
B
C
A
Table 3.Treatment Toxicity
Description
Number of 
%
patients (n = 84)
Neutropenia 3 3.6
Anemia 0 0.0
Hand-foot syndrome 65 77.4
Diarrhea 8 9.5
Mucositis 7 8.3
Nausea / Vomiting 29 34.5
Liver toxicity 11 13.1
Table 4.Summary Data on HFS
Number %
Patients
Total 84
With HFS 65 77.4
Severity of HFS
Grade 1 33 50.7
Grade 2 22 33.8
Grade 3 10 15.5
First episode of HFS
Cycle 1 17 26.1
Cycle 2 or later 45 73.9
Most severe episode of HFS
Cycle 1 3 4.5
Cycle 2 10 15.5
Cycle 3 13 20.0
Cycle 4 or later 39 60.0
Incidence grade Hand, Foot
Hand > Foot 0 0
Hand = Foot 22 34
Hand < Foot 43 66
HFS, hand-foot syndrome. interrupted for one cycle followed by adjustment of the
medication to 75% of the original dosage, and continued
with application of MEBO and supportive care in seven
patients; for two patients, the original dose was continued
with application of MEBO and supportive care, and one
patient discontinued treatment at the last cycle (the eighth
cycle) (Figs. 3 and 4).
Almost one million patients are diagnosed with colorectal
cancer every year, and half a million deaths from this
neoplasm occur annually worldwide.
7,8 Each year, appro-
ximately 230,000 patients with colon cancer are eligible
for adjuvant therapy.
7,8 Survival advantages have been
demonstrated with the administration of  bolus intravenous
fluorouracil plus leucovorin according to the Mayo Clinic
regimen (five days every month for six months) or the
Rosewell Park regimen (weekly bolus, six of every eight
weeks for eight months); this has been the standard care
for adjuvant treatment of colon cancer since the 1990s.
9
However, with the advent of the new oral fluropyrimidine,
capecitabine has been an effective alternative to intrave-
nous fluorouracil plus leucovorin for the adjuvant treatment
of colon cancer with significantly fewer adverse events.
2
Capecitabine is taken in the outpatient setting; it is
difficult to monitor treatment compliance and to detect
adverse events when compared to the IV chemotherapeutic
agents. HFS is a major adverse event that can interfere with
the general activities of daily living; therefore, intensive
management and care by medical personnel are necessary
to treat HFS. 
The mechanism responsible for HFS is unknown. For
patients receiving 5-FU, HFS is dose-dependent and it is
probably related to the accumulation of the drug in the skin.
One theory proposed to explain capecitabine-associated
HFS is that specialized skin cells (keratinocytes) might have
upgraded levels of the enzyme thymidine phosphorylase.
10
Another theory suggests that capecitabine may be
eliminated by the eccrine system (sweat secretion), and
HFS is caused by an unknown mechanism related to the
increased number of eccrine glands present in the hands
and feet.
11 In relation to this hypothesis, Grade 3 HFS has
been observed in the hands, feet, armpits, and genitals of
patients with hyperhidrosis. It is thought that more cases
Hyun-Sook Son, et al.
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Fig. 4. Management of hand-foot syndrome. (A) Grade 2 HFS; Painful erythema,
swelling/ discomfort that affects activity of daily living occurred, and the original
dose was maintained with application of MEBO for 1 cycle (3 weeks). (B) After
management, Grade 1 HFS; numbness, tingling, painless erythema / discomfort,
able to perform activities of daily living. (C) Grade 3 HFS; Pain moist desqu-
amation, ulceration, blistering, and severe pain / unable to perform daily living
activities occurred, and the drug administration was interrupted for one cycle (3
weeks). The patient was treated with MEBO. (D) After management, Grade 2
HFS; Painless erythema / discomfort, able to perform daily living activities.
B
CD
A
DISCUSSION
Fig. 3.Response to the treatment of hand-foot syndrome.occur during the summer season with regard to eccrine
gland involvement; but keratin and defection of the
epidermis are more likely to occur during the winter
season. In this study, the data were not studied by season
due to the small number of patients. 
Some studies have reported more toxic effects in the
areas of the hands compared to the feet; however, more
cases were found with the feet affected than the hands in
our study. This might be explained by friction, temperature
and the characteristics of ambulation after surgery for
colorectal cancer. However, the most widely accepted
hypothesis is that the capecitabine induces a direct toxic
effect against the epidermal cells due to the dose adminis-
tered. The histopathological findings are similar to other
sources of direct toxicity.
12
With regard to the safety of capecitabine monotherapy,
the majority of adverse events have been manageable and
reversible. Compared to a randomized phase III study,
13 the
most frequently reported adverse reaction in our study was
HFS, and the frequency was higher in the present study
(77.4% versus 54%, respectively); however, grade 3 HFS
was slightly lower (15.5% versus 17%, respectively). The
HFS was easily controlled by interruption of the chemo-
therapy protocol or dose reduction; and there was no case
with life threatening toxicity. A total of eight patients
(9.5%) discontinued treatment and one of these patients
(0.84%) stopped due to the HFS. In a phase III study,
13 2%
of the patients dropped out of the study because of the
HFS, and this rate was higher than the rate in our study. 
The cumulative nature of HFS has been difficult to
determine. Some investigators have found an increased
incidence of HFS,
14 while others have found no evidence
of cumulative HFS with capecitabine.
6 The results of our
study demonstrated that most of the first episodes of HFS
occurred during the second or more cycles of treatment.
This may be due to the cumulative effect of the drug; how-
ever, a delayed onset of the distinct toxic effects cannot be
completely ruled out. There is consensus among investi-
gators that interruption of the offending drug is the most
important step in the treatment of HFS.
6,13,15 Other inves-
tigators have proposed measures that include cold com-
presses and topical wound care.
16 There have been some
studies on the relief of HFS with the use of pyridoxine
(vitamin B-6).
17-19 We generally recommend petroleum-
based ointment and supportive care for grade 1 HFS, and a
dose reduction with ointment for grade 2 HFS.
The widely recommended skin barrier creams are used
for Grade 0 (preventive use) and Grade 1 HFS; MEBO is
used for Grade 2, and a dose reduction with ointment is
used for Grade 3. HFS is treated by patient education,
preventive management, ointment, conservative manage-
ment, dose reduction, and interruption of chemotherapy
administration, taking into consideration the patients’
condition and situation.  
In conclusion, HFS is manageable if both patient and
oncology care team are educated about the HFS associated
with treatment. The active participation of both patient and
oncology care team is a key element in the effective mana-
gement of HFS. Such efforts combined with the proper
dose reduction may lead to completion of the recom-
mended cycles, with a reduced frequency of HFS. 
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